Peter Leonardi

Peter Leonardi, Ph.D., M.B.A. – Co-Founder and CEO of OmniCyte. Dr. Leonardi’s previous positions include: CFO of Protein Sciences (a private biotech company which received FDA approval for the first and only approved recombinant seasonal Influenza vaccine, FluBlok) and grew from 45 employees to more than 100 during Peter's tenure, sold to Sanofi $750M, Director at Five Prime Advisors (a boutique Biotech Investment Bank), VP of Channel Development at ProCure Treatment Centers (a VC backed cancer treatment center), IBM and the NY Presbyterian Hospital (University hospital of Cornell and Columbia), IRB 2003 to 2008 and NCI SBIR study section 2016 to present. Peter has been issued several patents, including those for the platform technology for which our therapeutics are based.